Merck has announced plans to reduce WAC prices on Januvia, Janumet and Janumet XR effective Jan. 1, 2025. That means any inventory on your shelves on Dec. 31 will lose up to 40 percent of its value overnight and you won’t be able to recoup the loss.
To avoid unnecessary financial loss on Januvia, Janumet and Janumet XR inventory, we recommend you return any excess inventory on these products immediately.
Move to “on-demand inventory” for these items until Jan. 1, only ordering them when you have an adjudicated claim to fulfill. You should also inform patients on these products to call two days in advance for a refill.
Also check with your primary wholesaler for details on returns. Cardinal has announced they will not accept returns on these products after Dec. 1. Previously, McKesson has allowed returns up to 30 days before WAC reductions, which would also be Dec. 1. Remain attentive to your wholesaler communications as additional manufacturers may be planning WAC reductions. We will share any additional WAC reduction information that we receive.
Earlier this year, NCPA hosted a webinar to discuss the potential implications of upcoming WAC decreases and strategies for managing patient needs during the transition. The recording can be accessed here.
